Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Clin Cancer Res. 2013 Oct 28;19(22):6329–6330. doi: 10.1158/1078-0432.CCR-13-2007

Figure 1.

Figure 1

Staging scans at baseline and after 2 months of vemurafenib therapy in a patient with metastatic BRAF V600E–mutant conjunctival melanoma. A and B, marked growth in a left axillary lymph node mass. C and D, progression of a peripancreatic lymph node mass. E and F, modest regression in a mesenteric mass along with significant growth in a right paraspinal mass.